Second-generation antihistamines for the treatment of chronic idiopathic urticaria

Journal of Drugs in Dermatology

Volumn 9, Issue 5, 2010, Pages 503-512

  Belsito, Donald V ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESLORATADINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; TERFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST;

BACKACHE; BINDING AFFINITY; CHRONIC IDIOPATHIC URTICARIA; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EXTREMITY PAIN; FATIGUE; HEADACHE; HUMAN; MYALGIA; NAUSEA; PHARYNGITIS; PRURITUS; RECEPTOR OCCUPANCY; REVIEW; RHINOPHARYNGITIS; SEDATION; SINGLE DRUG DOSE; SKIN DISEASE; SOMNOLENCE; STOMACH DISCOMFORT; TREATMENT DURATION; XEROSTOMIA; BRAIN; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; QUALITY OF LIFE; URTICARIA;

BRAIN; CHRONIC DISEASE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; QUALITY OF LIFE; RECEPTORS, HISTAMINE H1; URTICARIA;

EID: 77953170011     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Docrat ME. Urticaria: A review and new therapeutic options. Curr Allergy Clin Immunol. 2006;19:145-150.
2. Kahan S, Smith EG. Urticaria. In a Page: Signs and Symptoms. Philadelphia, PA; Lippincott Williams & Wilkins. 2004:171-172.
3. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol. 2003;3:363-368. (Pubitemid 37254717)
4. Brunetti L, Francavilla R, Miniello VL, et al. High prevalence of autoimmune urticaria in children with chronic urticaria. J Allergy Clin Immunol. 2004;114:922-927. (Pubitemid 39330267)
5. Sabroe RA, Seed PT, Francis DM, et al. Chronic idiopathic urticaria: Comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Am Acad Dermatol. 1999;40:443-450. (Pubitemid 29115306)
6. Grob JJ, Revuz J, Ortonne JP, et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol. 2005;152:289-295. (Pubitemid 40343600)
7. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197-201. (Pubitemid 27062719)
8. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twicedaily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol. 2000;43(1 Pt 1):24-30. (Pubitemid 30439708)
9. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: Management of urticaria. Allergy. 2006;61:321-331.
10. Hadley JA. Evaluation and management of allergic rhinitis. Med Clin North Am. 1999;83:13-25. (Pubitemid 29031689)
11. Gonzalez MA, Estes KS. Pharmacokinetic overview of oral second- generation H1 antihistamines. Int J Clin Pharmacol Ther. 1998;36:292-300. (Pubitemid 28230177)
12. Minocha YC. Evaluation of H2 receptor antagonists in chronic idiopathic urticaria. Indian J Dermatol Venereol Leprol. 1995;61:265-267. (Pubitemid 26059902)
13. Phanuphak P, Schocket A, Kohler PF. Treatment of chronic idiopathic urticaria with combined H1 and H2 blockers. Clin Allergy. 1978;8:429-433. (Pubitemid 9053422)
14. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol. 2000;105(6 Pt 2):S622-S627. (Pubitemid 30399797)
15. Snyder SH, Snowman AM. Receptor effects of cetirizine. Ann Allergy. 1987;59(6 Pt 2):4-8. (Pubitemid 18026397)
16. Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003;31:312-318. (Pubitemid 36249686)
17. Polli JW, Baughman TM, Humphreys JE, et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J Pharm Sci. 2003;92:2082-2089. (Pubitemid 37175638)
18. Walsh GM, Annunziato L, Frossard N, et al. New insights into the second generation antihistamines. Drugs. 2001;61:207-236. (Pubitemid 32210197)
19. Whomsley R, Benedetti MS. Development of new H1 antihistamines: The importance of pharmacokinetics in the evaluation of safe and therapeutically effective agents. Curr Med Chem. 2005;4:451.
20. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-1518. (Pubitemid 23086411)
21. Zhang M-Q. Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem. 1997;4:171-184. (Pubitemid 27334341)
22. Xyzal [package insert]. Bridgewater, NJ, and Smyrna, GA: sanofiaventis US LLC, and UCB, Inc; 2008.
23. Allegra [package insert]. Bridgewater, NJ: sanofi-aventis US, LLC; 2007.
24. Lippert U, Kruger-Krasagakes S, Moller A, et al. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy- loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol. 1995;4(4 Pt 2):272-276.
25. Michel L, Murrieta-Aguttes M, Jean-Louis F, et al. Humoral and cellular responses to histamine and pollen allergen in a skin chamber model: Effect of mizolastine. Ann Allergy Asthma Immunol. 2000;85:64-69. (Pubitemid 30619418)
26. Simons FE, Simons KJ. H1 receptor antagonist treatment of chronic rhinitis. J Allergy Clin Immunol. 1988;81(5 Pt 2):975-980.
27. Zyrtec [package insert]. Smyrna, GA: UCB, Inc; 2006.
28. Clarinex [package insert]. Kenilworth, NJ: Schering Corporation; 2007.
29. Claritin [package insert]. Kenilworth, NJ: Schering-Plough Healthcare Products, Inc; 2000.
30. Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol. 1996;51:165-172.
31. Prenner B, Kim K, Gupta S, et al. Adult and pediatric poor metabolisers of desloratadine: An assessment of pharmacokinetics and safety. Expert Opin Drug Saf. 2006;5:211-223. (Pubitemid 43379620)
32. Allen J. Detail document #120819, new drug: Fexofenadine (Allegra). Pharmacists Lett. 1996;12:8.
33. Strolin Benedetti M, Whomsley R, Mathy FX, et al. Stereoselective renal tubular secretion of levocetirizine and dextrocetirizine, the two enantiomers of the H1-antihistamine cetirizine. Fundam Clin Pharmacol. 2008;22:19-23. (Pubitemid 351171281)
34. Abramovits W, Gupta A. Xyzal (levocetirizine dihydrochloride). Skinmed. 2008;7:84-85.
35. Tillement JP, Testa B, Bree F. Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem Pharmacol. 2003;66:1123-1126. (Pubitemid 37130287)
36. Gillard M, Benedetti MS, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res. 2005;54:367-369.
37. Hindmarch I, Johnson S, Meadows R, et al. The acute and subchronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin. 2001;17:241-255. (Pubitemid 34150432)
38. Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: Suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002;88:190-197. (Pubitemid 34165031)
39. Denham KJ, Boutsiouki P, Clough GF, Church MK. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res. 2003;52:424-427. (Pubitemid 37260429)
40. Gillard M, Van der Perren C, Moguilevsky N, et al. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: Contribution of Lys(191) and Thr(194). Mol Pharmacol. 2002;61:391-399. (Pubitemid 34112814)
41. Devalia JL, De Vos C, Hanotte F, Baltes E. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy. 2001;56:50-57. (Pubitemid 32099072)
42. Garg G, Thami GP. Comparative efficacy of cetirizine and levocetirizine in chronic idiopathic urticaria. J Dermatolog Treat. 2007;18:23-24. (Pubitemid 46410637)
43. Breneman D, Bronsky EA, Bruce S, et al. Cetirizine and astemizole therapy for chronic idiopathic urticaria: A double-blind, placebo-controlled, comparative trial. J Am Acad Dermatol. 1995;33(2 Pt 1):192-198.
44. Breneman DL. Cetirizine versus hydroxyzine and placebo in 44. chronic idiopathic urticaria. Ann Pharmacother. 1996;30:1075-1079. (Pubitemid 26332861)
45. Kalivas J, Breneman D, Tharp M, et al. Urticaria: Clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol. 1990;86(6 Pt 2):1014-1018.
46. Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol. 2006;45:469-474.
47. Nettis E, Colanardi MC, Barra L, et al. Levocetirizine in the treatment of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. Br J Dermatol. 2006;154:533-538. (Pubitemid 43382664)
48. Kapp A, Wedi B. Chronic urticaria: Clinical aspects and focus on a new antihistamine, levocetirizine. J Drugs Dermatol. 2004;3:632-639.
49. Bernstein IL, Bernstein DL. The efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticaria. J Allergy Clin Immunol. 1988;81:211.
50. Monroe EW, Fox RW, Green AW, et al. Efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticaria. J Am Acad Dermatol. 1988;19:138-139.
51. Lachapelle JM, Decroix J, Henrijean A, et al. Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol. 2006;20:288-292.
52. Grob JJ, Auquier P, Dreyfus I, Ortonne JP. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: A randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol. 2008;22:87-93.
53. Spector SL, Shikiar R, Harding G, et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis. 2007;79:157-162.
54. Kaplan AP, Spector SL, Meeves S, et al. Once-daily fexofenadine treatment for chronic idiopathic urticaria: A multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2005;94:662-669. (Pubitemid 40847153)
55. Potter P. Levocetirizine is superior to desloratadine in improving symptoms of chronic idiopathic urticaria: A double-blind, randomized clinical trial [abstract P265]. Ann Allergy Asthma Immunol. 2008;A94.
56. Potter P. Levocetirizine is superior to desloratadine in improving symptoms of chronic idiopathic urticaria: A double-blind, randomized clinical trial [poster P265]. Presented at: American College of Allergy, Asthma and Immunology, Dallas, TX. November 8-17, 2007.
57. Barbaud A. Levocetirizine has a better overall efficacy than desloratadine in chronic idiopathic urticaria: A double-blind, randomized, clinical trial [abstract 517]. World Allergy Org J. 2007;Suppl:S165.
58. Barbaud A. Levocetirizine has a better overall efficacy than desloratadine in chronic idiopathic urticaria: A double-blind, randomized, clinical trial [poster 517]. Presented at: 20th World Allergy Congress, Bangkok, Thailand. December 2-6, 2007.
59. Patel P, Danzig M. Comparative efficacy and safety of loratadine and cetirizine in patients with chronic idiopathic urticaria. Adv Ther. 1997;14:318-322. (Pubitemid 28049567)
60. Sale ME, Barbey JT, Woosley RL, et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther. 1994;56:295-301. (Pubitemid 24323921)
61. Simons FER, for the Early Treatment of Asthma in Atopic Children (ETAC) Study Group. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. J Allergy Clin Immunol. 1999;104(2 Pt 1):433-440.
62. Simons FER, Silas P, Portnoy JM, et al. Safety of cetirizine in infants 6 to 11 months of age: A randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2003;111:1244-1248. (Pubitemid 36683677)
63. Winder JA, Noonan MJ, Lumry WR, et al. Absence of QT(c) prolongation with cetirizine in children aged 6 to 11 years. Pediatr Asthma Allergy Immunol. 1996;10:181-190.
64. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104:927-933. (Pubitemid 29532110)
65. Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "non- sedating"antihistamines: Four prescription-event monitoring studies in general practice. BMJ. 2000;320:1184-1187. (Pubitemid 30224270)
66. De Vos C, Mitchev K, Pinelli M-E, et al. Non-interventional study comparing treatment satisfaction in patients treated with antihistamines. Clin Drug Investig. 2008;28:221-230. (Pubitemid 351414746)
67. Hulhoven R, Rosillon D, Letiexhe M, et al. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007;63:1011-1017. (Pubitemid 47561809)
68. Yanai K, Ryu JH, Watanabe T, et al. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol. 1995;116:1649-1655.
69. Tashiro M, Sakurada Y, Iwabuchi K, et al. Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004;44:890-900. (Pubitemid 38971571)
70. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci. 2002;72:409-414. (Pubitemid 35452554)
71. Warren R, Simpson H, Hilchie H. Drugs detected in fatally injured drivers in the province of Ontario. In: Goldberg L, ed. Alcohol, Drugs, and Traffic Safety Vol. I. Stockholm, Sweden: Almquist and Wiksell; 1981:203-217.
72. Verster JC, Volkerts ER. Antihistamines and driving ability: Evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol. 2004;92:294-304. (Pubitemid 38380785)
73. Verster JC, De Weert AM, Bijtjes SIR, et al. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: A randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2003;169:84-90. (Pubitemid 37088618)
74. Simons FE, Simons KJ. Levocetirizine: Pharmacokinetics and pharmacodynamics in children age 6 to 11 years. J Allergy Clin Immunol. 2005;116:355-361. (Pubitemid 41096543)
75. Simons FER, for the Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatr Allergy Immunol. 2007;18:535-542.